Life Sciences & Healthcare in Greece

We are pleased to present Deloitte’s Life Sciences and Healthcare in Greece | The Road Ahead. 

Deloitte Greece’s new report examines the status of the Greek Healthcare and Life Sciences sectors in terms of expenditure, infrastructure and competition and summarizes the recent healthcare regulatory changes affecting the Greek market. 

Highlights of the report include the following:

• On 20th August 2018, Greece completed its stability program and concluded a period of 8 years of recession.

• Healthcare spending, after reaching its peak in 2009, decreased by approx. 40% during the period 2009-2016, in line with a drop of more than 60% in pharmaceutical spending.

• Pharmaceutical companies’ liquidity was also impacted by the Rebates and Clawbacks mechanism, the value of which increased by approx. 300% between 2012 and 2016.

• For the first time since the beginning of the crisis, healthcare spending grew by an average annual increase of 1.2% between 2014 and 2016. In the same period Pharmaceutical spending stabilized, following an average annual drop of 0.9%.